CALL: (661) 257-8400

Chemical Peels

Combat aging, repair sun damage, and treat acne with top-of-the-line chemical peels.

CALL NOW!

Best for treating:

Discoloration

Acne

Texture

fine Lines

Aging and UV exposure cause noticeable damage to the outer layers of our skin.

Many of us suffer from discoloration, fine lines, melasma, enlarged pores, laxity, and irregular texture. Not only do chemical peels yield notable results at a lower cost than laser treatments, peels are also an excellent alternative for patients with darker skin tones on which lasers cannot be safely used.

The Solutions

ZO 3-Step Peel

The ZO 3-Step Peel is an in-office peel followed by an at-home treatment for longer-lasting results.

 The peel solution contains lactic acid, TCA, and salicylic acid to exfoliate the outer layer of the epidermis. Antioxidant-rich Stimulating Retinol Creme is then applied to boost collagen production and promote the regeneration of healthy new cells. Finally, the Calming Creme is applied to restore moisture and minimize irritation. Patients can expect dead skin to slough off 2-4 days following the procedure, revealing smooth, soft, glowing new skin. This type of peel can be customized to treat active acne and is great for targeting melasma, fine lines, rough texture, large pores, and dullness. It’s suitable for all skin types.

VI Peel

The VI Peel is another fan favorite popular for its nourishing blend of minerals, salicylic acid, vitamin C, retonoic acid, and more.

Like the ZO 3-Step Peel, the VI Peel is excellent for improving texture, tone, radiance and clarity. Acids in the peel work to remove dull, damaged skin and vitamins stimulate the production of collagen to erase lines, shrink pores, and reduce discoloration in as little as 1 week. The peel solution is applied painlessly during an in-office visit of less than 1 hour. Once the solution dries, patients can leave and resume normal activity as the ingredients get to work. After 5 hours you can wash your face and peeling will begin within 2-4 days. The VI Peel is specifically formulated to rejuvenate aging skin and help prevent future damage for all skin types. 

Before

After

Before

After

“I get a peel twice a year and the results are phenomenal. The ZO peel has completely gotten rid of my adult acne and it leaves my skin baby soft and smooth. I absolutely love it.”
- A.A.

Dr. Ingber, M.D.

Dermacure is an aesthetic medical office owned and operated by Craig Ingber, MD a board certified Facial Plastic Surgeon.

Dr. Ingber is a clinical instructor of surgery at UCLA Medical School and performs all injections upon request. He is a top 1% injector of Botox and Juvederm in the nation and is the #1 physician injector in Santa Clarita Valley.

LEARN MORE ABOUT DR. INGBER

Exfoliate dull, damaged skin to reveal youthful and glowing skin today!

Read More

KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information

INDICATION
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS 
KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

ADVERSE REACTIONS
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

*Individual results may vary.

Exfoliate dull, damaged skin to reveal youthful and glowing skin today!

Read More

KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information

INDICATION
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS 
KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

ADVERSE REACTIONS
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

*Individual results may vary.

I'm Interested!

Please contact me with more information on this procedure.

©2018 DermaCure Valencia | Web Design by Small Dog Creative